Exceeding Projections
Source: iQoncept / Shutterstock
NeuroSense Therapeutics (NASDAQ:NRSN) has unveiled the much-anticipated results for the fourth quarter of 2023.
- With earnings per share standing at -16 cents, NeuroSense Therapeutics has once again defied expectations, surpassing the forecasted EPS of -23 cents.
- While revenue data was conspicuously absent for the quarter, the positive EPS revelation has undoubtedly turned heads in the investor community.
Adapted from InvestorPlace Media, the ultimate resource for financial news: https://investorplace.com/earning-results/2024/04/nrsn-stock-earnings-neurosense-therapeutics-for-q4-of-2023/.
©2024 InvestorPlace Media, LLC